Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Padmanee Sharma

Showing results (61-70 of 216) with videos related to

Pageof 22
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 3, 2024
The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role?Anna Maria Di Giacomo, Michael Lahn, Alexander Mm Eggermont, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2018
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3<sup>+</sup> Regulatory T Cells (Tregs) in Human CancersAnu Sharma, Sumit K Subudhi, Jorge Blando, et al.
Nature Communications|February 15, 2017
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunityDmitriy Zamarin, Rikke B Holmgaard, Jacob Ricca, et al.
Cancer Cell|October 17, 2025
TET2-mutant clonal hematopoiesis enhances macrophage antigen presentation and improves immune checkpoint therapy in solid tumorsShelley Herbrich, Mehdi Chaib, Swetha Anandhan, et al.
Cancer Immunology Research|April 30, 2014
CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapyHong Chen, Tihui Fu, Woong-Kyung Suh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2020
Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275Matthew D Galsky, Abdel Saci, Peter M Szabo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cellsSacha Gnjatic, Nasser K Altorki, Derek Ng Tang, et al.
Cancer Immunology Research|July 11, 2019
Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular CarcinomaAhmed Omar Kaseb, Luis Vence, Jorge Blando, et al.
Journal of Hematology & Oncology|September 7, 2016
Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case reportMarc Uemura, Van A Trinh, Cara Haymaker, et al.
Nature Communications|August 9, 2016
Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapyLewis Zhichang Shi, Tihui Fu, Baoxiang Guan, et al.
Pageof 22

Showing results (61-70 of 216) with videos related to

Sort By:
Pageof 22
European Journal of Cancer (Oxford, England : 1990)|January 3, 2024
The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role?Anna Maria Di Giacomo, Michael Lahn, Alexander Mm Eggermont, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2018
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3<sup>+</sup> Regulatory T Cells (Tregs) in Human CancersAnu Sharma, Sumit K Subudhi, Jorge Blando, et al.
Nature Communications|February 15, 2017
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunityDmitriy Zamarin, Rikke B Holmgaard, Jacob Ricca, et al.
Cancer Cell|October 17, 2025
TET2-mutant clonal hematopoiesis enhances macrophage antigen presentation and improves immune checkpoint therapy in solid tumorsShelley Herbrich, Mehdi Chaib, Swetha Anandhan, et al.
Cancer Immunology Research|April 30, 2014
CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapyHong Chen, Tihui Fu, Woong-Kyung Suh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2020
Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275Matthew D Galsky, Abdel Saci, Peter M Szabo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cellsSacha Gnjatic, Nasser K Altorki, Derek Ng Tang, et al.
Cancer Immunology Research|July 11, 2019
Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular CarcinomaAhmed Omar Kaseb, Luis Vence, Jorge Blando, et al.
Journal of Hematology & Oncology|September 7, 2016
Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case reportMarc Uemura, Van A Trinh, Cara Haymaker, et al.
Nature Communications|August 9, 2016
Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapyLewis Zhichang Shi, Tihui Fu, Baoxiang Guan, et al.
Pageof 22